Alkermes plc (ALKS) — Fair Value Analysis

Base-case fair value (P50): $62.59 · Current price: $53.69 · Verdict: Undervalued

The Verdict on ALKS

Monte Carlo simulations suggest ALKERMES (ALKS) is currently Fairly Valued. Despite its current trading price of $53.69, our analysis indicates a median fair value (P50) of $62.59, implying a potential +16.6% from current levels. This valuation accounts for a comprehensive range of future operational and market scenarios, placing ALKS within a reasonable range given its sector and fundamental outlook. The simulation’s robust modeling, leveraging thousands of potential paths, grounds this assessment, helping investors gauge the underlying intrinsic worth against today's market dynamics.

How ALKS stacks up against Healthcare

ALKS operates within the dynamic Healthcare sector, a landscape marked by both innovation and regulatory complexities. Our quality tier assessment places ALKS as "average" regarding its operational and financial health relative to its sector peers. This average standing influences its fair value, suggesting that while ALKS exhibits a potential +16.6% towards the $62.59 median, it also faces industry-typical challenges and opportunities. The $53.69 reflects market perceptions of these factors, positioning it in line with an average-tier company within the Healthcare space.

What this means for investors

For investors, the Fairly Valued verdict combined with the potential +16.6% to $62.59 means ALKS is trading at a price that our simulations deem appropriate, though with some room for appreciation. The $53.69 doesn't signal significant undervaluation or overvaluation, but rather a balanced outlook based on the probabilistic distribution of future outcomes. Understanding that the median fair value of $62.59 suggests a notable gap from $53.69 is key. To explore the full bear-case and bull-case distributions, along with the probability of upside, sign up for a free FairCurve account and track ALKS's fair value as new fundamentals are released.